MedTrace Logo

Ziprasidone in the Psychosis Prodrome

NCT00635700 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2023-03-27

Study results available
· View outcomes & findings →

Summary

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Conditions

  • Psychosis Prodrome

Interventions

DRUG

ziprasidone

20-160 mg/d

DRUG

placebo

placebo

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Scott W Woods, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00635700 on ClinicalTrials.gov